Literature DB >> 31431542

Reverse signaling by semaphorin 4C elicits SMAD1/5- and ID1/3-dependent invasive reprogramming in cancer cells.

Sreeharsha Gurrapu1, Giulia Franzolin1,2, Damon Fard1,2, Massimo Accardo1, Enzo Medico2,3, Ivana Sarotto4, Anna Sapino4,5, Claudio Isella2,3, Luca Tamagnone6,7.   

Abstract

Semaphorins are a family of molecular signals that guide cell migration and are implicated in the regulation of cancer cells. In particular, transmembrane semaphorins are postulated to act as both ligands ("forward" mode) and signaling receptors ("reverse" mode); however, reverse semaphorin signaling in cancer is relatively less understood. Here, we identified a previously unknown function of transmembrane semaphorin 4C (Sema4C), acting in reverse mode, to elicit nonconventional TGF-β/BMP receptor activation and selective SMAD1/5 phosphorylation. Sema4C coimmunoprecipitated with TGFBRII and BMPR1, supporting its role as modifier of this pathway. Sema4C reverse signaling led to the increased abundance of ID1/3 transcriptional factors and to extensive reprogramming of gene expression, which suppressed the typical features of the epithelial-mesenchymal transition in invasive carcinoma cells. This phenotype was nevertheless coupled with burgeoning metastatic behavior in vivo, consistent with evidence that Sema4C expression correlates with metastatic progression in human breast cancers. Thus, Sema4C reverse signaling promoted SMAD1/5- and ID1/3-dependent gene expression reprogramming and phenotypic plasticity in invasive cancer cells.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31431542     DOI: 10.1126/scisignal.aav2041

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  5 in total

Review 1.  Role of Cadherins in Cancer-A Review.

Authors:  Ilona Kaszak; Olga Witkowska-Piłaszewicz; Zuzanna Niewiadomska; Bożena Dworecka-Kaszak; Felix Ngosa Toka; Piotr Jurka
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

Review 2.  Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer.

Authors:  Roberta Mastrantonio; Hua You; Luca Tamagnone
Journal:  Theranostics       Date:  2021-01-15       Impact factor: 11.556

Review 3.  Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy.

Authors:  Zhengxiao Zhao; Zhiyuan Bo; Weiyi Gong; Yong Guo
Journal:  Int J Med Sci       Date:  2020-04-06       Impact factor: 3.738

Review 4.  The Prowess of Andrographolide as a Natural Weapon in the War against Cancer.

Authors:  Ammad Ahmad Farooqi; Rukset Attar; Uteuliyev Yerzhan Sabitaliyevich; Nada Alaaeddine; Damião Pergentino de Sousa; Baojun Xu; William C Cho
Journal:  Cancers (Basel)       Date:  2020-08-04       Impact factor: 6.639

5.  High SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma.

Authors:  Yufang Hou; Weiqi Wang; Zifan Zeng; Wenqiang Gan; Silin Lv; Tiegang Li; Zheng Yan; Rixin Zhang; Min Yang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.